- Home
- TKO vs ROIV Comparison
TKO vs ROIV Comparison
Compare TKO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKO
- ROIV
- Stock Information
- Founded
- TKO 1980
- ROIV 2014
- Country
- TKO United States
- ROIV United Kingdom
- Employees
- TKO N/A
- ROIV N/A
- Industry
- TKO
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TKO
- ROIV Health Care
- Exchange
- TKO Nasdaq
- ROIV Nasdaq
- Market Cap
- TKO 13.3B
- ROIV 7.8B
- IPO Year
- TKO N/A
- ROIV N/A
- Fundamental
- Price
- TKO $170.83
- ROIV $11.40
- Analyst Decision
- TKO Strong Buy
- ROIV Buy
- Analyst Count
- TKO 14
- ROIV 4
- Target Price
- TKO $163.77
- ROIV $17.50
- AVG Volume (30 Days)
- TKO 986.8K
- ROIV 7.9M
- Earning Date
- TKO 08-06-2025
- ROIV 08-07-2025
- Dividend Yield
- TKO 0.88%
- ROIV N/A
- EPS Growth
- TKO N/A
- ROIV N/A
- EPS
- TKO 1.17
- ROIV N/A
- Revenue
- TKO $2,850,693,000.00
- ROIV $29,053,000.00
- Revenue This Year
- TKO $61.11
- ROIV $3.28
- Revenue Next Year
- TKO $24.35
- ROIV $156.84
- P/E Ratio
- TKO $146.40
- ROIV N/A
- Revenue Growth
- TKO 10.04
- ROIV N/A
- 52 Week Low
- TKO $102.46
- ROIV $8.73
- 52 Week High
- TKO $182.60
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- TKO 49.02
- ROIV 54.55
- Support Level
- TKO $169.49
- ROIV $10.71
- Resistance Level
- TKO $173.04
- ROIV $11.58
- Average True Range (ATR)
- TKO 3.92
- ROIV 0.29
- MACD
- TKO -1.08
- ROIV 0.00
- Stochastic Oscillator
- TKO 17.31
- ROIV 62.16
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sport and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates the majority of its revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's global live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.